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Abstract
Background: The described relationship between Alzheimer’s disease (AD) and type 2 diabetes (T2D) and the fact
that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD
pathology.
Main body: Although T2D treatment has evident limitations, options are increasing including glucagon-like peptide
1 analogs. Among these, liraglutide (LRGT) is commonly used by T2D patients to improve β cell function and
suppress glucagon to restore normoglycaemia. Interestingly, LRGT also counterbalances altered brain metabolism
and has anti-inflammatory properties. Previous studies have reported its capacity to reduce AD pathology, including
amyloid production and deposition, tau hyperphosphorylation, or neuronal and synaptic loss in animal models of
AD, accompanied by cognitive improvement. Given the beneficial effects of LRGT at central level, studies in patients
have been carried out, showing modest beneficial effects. At present, the ELAD trial (Evaluating Liraglutide in
Alzheimer’s Disease NCT01843075) is an ongoing phase IIb study in patients with mild AD. In this minireview, we
resume the outcomes of LRGT treatment in preclinical models of AD as well as the available results in patients up
to date.
Conclusion: The effects of LRGT on animal models show significant benefits in AD pathology and cognitive
impairment. While studies in patients are limited, ongoing clinical trials will probably provide more definitive
conclusions on the role of LRGT in AD patients.
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia. Type 2 diabetes (T2D) may increase the risk
to suffer AD over two-fold [1, 2]. However, it remains
unclear whether T2D and AD are parallel phenomena or
synergistic diseases linked by vicious pathological cycles
[3]. In this sense, findings in patients relating T2D to
AD classical pathology are inconsistent [4]. However,
T2D increases the risk to develop AD, even after
adjusting for vascular risk factors [5, 6] and if only 10%
of diabetic patients end up suffering AD, the number of
AD patients will double [2]. This situation and the fact
that AD has no successful treatment supports the study
of antidiabetic drugs that may reduce or slow down AD
pathology.
Liraglutide (LRGT) is a glucagon-like peptide 1(GLP-
1) analog that has been widely assessed in animal models
of AD. Initial studies with patients have shown modest
beneficial effects and it is currently under evaluation in
the ELAD trial (Evaluating Liraglutide in Alzheimer’s
Disease NCT01843075). We have reviewed available
bibliography on the potential mechanisms through
which LRGT may benefit AD. An overall improvement
of brain metabolic alterations, amyloid (Aβ) and tau
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pathologies, inflammation, and neuronal damage are ob-




Glucagon-like peptide 1 (GLP-1) is implicated in the
control of glycemia and metabolic homeostasis, both in
the periphery and the central nervous system [7, 8]. Due
to the importance of GLP-1 signaling on cognitive func-
tion [9] and the relationship between AD and T2D [10],
GLP-1 analogs, and LRGT specifically, may provide a
relevant venue to ameliorate AD pathology [11]. Previ-
ous studies have shown some controversial outcomes in
AD models. Whereas brain weight [12, 13], hippocampal
insulin [13–16], cortical glucose levels or brain GLUT1
and GLUT4 [13] do not seem to be affected, LRGT
treatment increases GLP1-receptors in the hippocampus
of AD mice [15–17]. Similarly, LRGT also increases in-
sulin receptor levels in a primate model of AD [14], al-
though no differences have been observed in AD mice
[18]. LRGT ameliorates insulin resistance in the hippo-
campus by reducing phosphorylated insulin receptor
levels [19, 20] and insulin receptor substrate-1 [19, 20].
Interestingly, insulin degrading enzyme, that is reduced
in AD preclinical models and a feasible underlying
mechanism for AD and T2D [21, 22], is preserved or in-
creased in the cortex and hippocampus from AD mice
after LRGT treatment [18, 20].
Autopsy cohort studies have revealed a limited role of
T2D on classical AD neuropathological features (amyl-
oid (Aβ) plaques and tau tangles) [4]. However, studies
in animals show an overall improvement after different
administration protocols [12, 13, 23, 24], including
prophylactic [23] and long-term treatments [23, 25–27].
Whereas some studies have reported no effects on amyl-
oid pathology [28], the majority of the results show that
LRGT dramatically reduces Aβ plaque size [29], number
[19, 29], and burden [18, 23, 30–32]. LRGT also de-
creases Aβ aggregates [30] and restores increased levels
of β-secretase 1 and presenilin 1 [17] in the brain from
an AD mice, once Aβ pathology is fully established (Fig.
1). Moreover, positive effects have also been observed
when LRGT is administered before Aβ plaques deposit
[23]. In addition, LRGT limits tau hyperphosphorylation
by modulating the activity of ERK and JNK in 3xTgAD
[12, 13], APP/PS1 [29], and hTauP301L mice [33]. Like-
wise, LRGT reduces hippocampal tau phosphorylation
by modulating Akt and GSK-3β [15], and in hyperhomo-
cysteinemic rats, tau hyperphosphorylation is reduced
through the activation of PP2Ac [17]. Likewise, LRGT
neuroprotection is mediated by a reduction of neurofila-
ment phosphorylation in 3xTgAD animals [12]. LRGT
also improves synaptic plasticity [18, 34], density [14],
structure [15, 27], and synapsis number [35], increasing
synaptophysin and PSD-95 levels in AD mice [23, 30,
35] together with increased long-term potentiation and
paired-pulse facilitation [18, 30, 34, 35]. NMDA
synapse-associated proteins are restored by LRGT in the
hippocampus from hyperhomocysteinemic rats [17], and
cAMP/PKA pathway is also improved [14, 34]. Addition-
ally, LRGT not only attenuates neural loss and degener-
ation, but it also increases neurogenesis in the cortex
[18, 23, 26, 35] and the subventricular zone [31, 32], re-
duces the number of degenerating cells in the cortex
and hippocampus [12], and increases cell proliferation in
the dentate gyrus of AD animals [26]. Inflammation is
also a major feature in AD and previous studies show
Fig. 1 Schematic effects of liraglutide in the brain with AD pathology
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that LRGT reduces microgliosis and astrocytosis in the
cortex [19, 23, 30, 35] and hippocampus [29, 31, 32]. Be-
sides, LRGT limits pro-inflammatory cytokines, includ-
ing TNF-α, IL-1ß, or IL-10 [13, 24]. In line with these
observations, LRGT also decreases brain oxidative stress,
by reducing glucose-6-phosphate dehydrogenase activity,
the formation of cortical carbonyl groups, nitrite and 8-
hydroxy-2′-deoxyguanosine in 3xTgAD mice [13]. Simi-
larly, oxidative phosphorylation of cortical astrocytes is
reduced in 5xFAD mice [27] (Fig. 1).
The positive effects of LRGT on AD-like pathology
support the beneficial role of LRGT on learning and
memory in most of the studies. In this sense, spatial
working memory improves after LRGT treatment [12,
15, 17, 18, 24], and LRGT also restores episodic memory
in AD models [14, 18, 23] (Fig. 1). In line with these ob-
servations, contextual fear conditioning [14], active-
avoidance T-maze task [25], or clasping behavior [33]
are also improved by LRGT, while locomotor activity
does not seem affected [12, 17, 23].
Studies in AD patients
The above described outcomes in preclinical models of
AD have set the basis to futher assess LRGT in patients.
Whereas other antidiabetic drugs, including GLP-1 ana-
logs or dipeptidyl peptidase 4 inhibitors, have been part
of preceding or ongoing clinical trials, studies with
LRGT specifically are still limited. Previous meta-
analysis has shown a pro-cognitive class effect of antidia-
betic agents in AD/mild cognitive impairment, although
the actual beneficial effects with LRGT are limited [36].
LRGT administration to individuals with subjective cog-
nitive complaints, at risk for AD, improves intrinsic con-
nectivity within brain areas. While this did not translate
into cognitive differences between study groups after 12
weeks of treatment [37], other studies have shown that
treatment with LRGT to AD patients for 6 months raises
blood-brain glucose transfer capacity, restoring glucose
transport [38], as an initial requirement to improve brain
alterations. Gejl et al. [39] (ClinicalTrials.gov NCT0146
9351) have also reported that treatment with LRGT to
AD patients for 6 months prevents cerebral metabolic
rate of glucose consumption decline, as an indicator of
cognitive impairment, synaptic dysfunction, and disease
evolution. Whereas Aβ load or cognition do not seem to
be affected, the authors state the study was underpow-
ered. Another study with pre- or early diabetes patients
has recently shown that LRGT improves short-term
memory and memory composite in treated patients [40].
The ELAD trial is presently ongoing and the main objec-
tives include evaluation of glucose metabolic consump-
tion in cortical regions and cognition, MRI changes,
microglial activation, and amyloid or tau changes [41],
and the latest results will be published shortly.
Conclusions
Preclinical studies show beneficial effects of LRGT on
AD pathological features and cognition. While the stud-
ies in patients have only shown moderate positive ef-
fects, the ongoing ELAD trial may provide relevant
insights on the actual role of LRGT at central level and
open new venues of treatment for AD patients.
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